urothelial carcinoma

1 curated biomarker

← Back to browse

FDA-approved treatments

PD-L1
- Tecentriq (atezolizumab) [fda]
- Imfinzi (durvalumab) [fda]
- Opdivo (nivolumab) [fda]
- Keytruda (pembrolizumab) [ema]

Prevalence

PD-L1
PD-L1 expression thresholds and prevalence vary substantially by tumor type and assay; high PD-L1 expression (TPS >= 50%) is seen in approximately 25%-30% of NSCLC by validated companion diagnostic assays.[fda]

Tests / detection method

PD-L1
IHC

Therapeutic pipeline

PD-L1
- Next-generation immune checkpoint combinations (e.g., LAG-3, TIGIT co-blockade) (LAG-3 expression, TIGIT expression) [fda]

PubMed Central · Oct 1, 2026
Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.
Read at PubMed Central
PubMed Central · Sep 2, 2026
Lynch syndrome-associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Regional Variation in Bladder Cancer Clinical Trial Availability in the US.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery.
- KRAS (biomarker)
Read at PubMed Central
PubMed Central · Sep 1, 2026
Cathepsin V (CTSV) Shapes the Epigenetic-Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker.
Read at PubMed Central
PubMed Central · Sep 1, 2026
Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.
Read at PubMed Central
PubMed Central · Sep 1, 2026
CircFut8 Suppresses Bladder Cancer by Modulating SRSF9-Dependent Pre-mRNA Splicing.
Read at PubMed Central
PubMed Central · Aug 29, 2026
Bladder cancer precision-cut tumor slices (PCTS) preserve functional immune microenvironment enabling ex vivo drug evaluation.
Read at PubMed Central
PubMed Central · Aug 29, 2026
Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 21, 2026
Fruit and vegetable consumption, dietary and plasma carotenoids and risks of recurrence and progression in patients with non-muscle-invasive bladder cancer.
Read at PubMed Central
PubMed Central · Aug 21, 2026
Iron Oxide Nanozyme for Magnetothermal Activation of ER-TRPV1 Enables Efficient Intravesical Therapy of Bladder Cancer.
Read at PubMed Central
PubMed Central · Aug 21, 2026
Outcomes and Predictive Factors for Gynecologic Organ Involvement in Radical Cystectomy for Female Bladder Cancer Patients: A Multicenter Retrospective Cohort Study.
Read at PubMed Central
PubMed Central · Aug 20, 2026
[Everolimus inhibits malignant phenotype of erdafitinib-resistant bladder cancer cells through the p70S6K/PI3K/MAPK signaling pathway].
Read at PubMed Central
PubMed Central · Aug 20, 2026
Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential.
Read at PubMed Central
PubMed Central · Aug 20, 2026
Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as treatment for HER2-expressing advanced urothelial cancer in China.
- ERBB2 (biomarker)
Read at PubMed Central
PubMed Central · Aug 19, 2026
Sexual life and intimate relationship experience among bladder cancer patients: a systematic review and qualitative meta-synthesis.
Read at PubMed Central
PubMed Central · Aug 18, 2026
[CRISPR-Cas9 activation screening identifies candidate chemokine regulators of ter-tiary lymphoid structure formation in bladder cancer].
Read at PubMed Central

urothelial carcinoma

FDA-approved treatments

Prevalence

Tests / detection method

Therapeutic pipeline

Recent news for urothelial carcinoma

Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.

Lynch syndrome-associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort.

Depletion of Soluble PD-L1 with Engineered Nanoparticles Promotes Antitumor Immunity and Tumor Control.

Regional Variation in Bladder Cancer Clinical Trial Availability in the US.

Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.

Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery.

Cathepsin V (CTSV) Shapes the Epigenetic-Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker.

Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.

CircFut8 Suppresses Bladder Cancer by Modulating SRSF9-Dependent Pre-mRNA Splicing.

Bladder cancer precision-cut tumor slices (PCTS) preserve functional immune microenvironment enabling ex vivo drug evaluation.

Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort.

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.

Fruit and vegetable consumption, dietary and plasma carotenoids and risks of recurrence and progression in patients with non-muscle-invasive bladder cancer.

Iron Oxide Nanozyme for Magnetothermal Activation of ER-TRPV1 Enables Efficient Intravesical Therapy of Bladder Cancer.

Outcomes and Predictive Factors for Gynecologic Organ Involvement in Radical Cystectomy for Female Bladder Cancer Patients: A Multicenter Retrospective Cohort Study.

[Everolimus inhibits malignant phenotype of erdafitinib-resistant bladder cancer cells through the p70S6K/PI3K/MAPK signaling pathway].

Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential.

Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as treatment for HER2-expressing advanced urothelial cancer in China.

Sexual life and intimate relationship experience among bladder cancer patients: a systematic review and qualitative meta-synthesis.

[CRISPR-Cas9 activation screening identifies candidate chemokine regulators of ter-tiary lymphoid structure formation in bladder cancer].